Quick Answer
Mereo BioPharma Group plc reported Operating Income of -$40.11 million for fiscal year 2025.
Mereo BioPharma Group plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$40.11M | +15.3% |
| 2024 | -$47.36M | -66.7% |
| 2023 | -$28.42M | +47.8% |
| 2022 | -$54.43M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$10.02M | -6.8% | +4.6% |
| June 30, 2025 | -$10.50M | +18.1% | +6.3% |
| March 31, 2025 | -$11.20M | -13.2% | -19.5% |
| September 30, 2024 | -$9.37M | -3.4% | +26.9% |
| June 30, 2024 | -$12.81M | -1480.0% | -29.4% |
| March 31, 2024 | -$9.90M | +13.2% | -9.2% |
| September 30, 2023 | -$9.07M | — | -1018.0% |
| June 30, 2023 | -$811.0K | — | +92.9% |
- Mereo BioPharma Group plc showed an increase of +15.3% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Mereo BioPharma Group plc’s operating income has grown by 26.3% (from -$54.43 million to -$40.11 million).
- The most recent figure is from Mereo BioPharma Group plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: